Thrombosis News and Research

Latest Thrombosis News and Research

Nordion presents TheraSphere Phase II trial results against liver metastases at SIR meeting

Nordion Inc., a leading provider of products and services to the global health science market, today shared results from the first multi-site, Phase II clinical trial to evaluate TheraSphere® for treatment of metastatic liver cancer.

29 Mar 2011

Drugs for prevention of breast cancer

According to an international panel of cancer experts, women at high risk of developing breast cancer should be given preventative drugs. The experts write in the Lancet Oncology adding, drugs such as tamoxifen could reduce the chances of developing breast cancer. They suggest that this would be something similar to prescribing statins to patients at risk of heart disease. But tamoxifen has been linked with womb cancer, blood clots and stroke.

28 Mar 2011

Merck to return rights for betrixaban to Portola

Portola Pharmaceuticals and Merck, known as MSD outside the United States and Canada, today announced that Merck plans to return to Portola all rights for betrixaban, an investigational oral Factor Xa inhibitor anticoagulant being evaluated for the prevention of stroke in patients with atrial fibrillation (SPAF). This decision was made following a review of Merck's investigational portfolio.

25 Mar 2011

Dabigatran etexilate is less costly, more effective for stroke treatment in patients with AF

A new economic analysis, published online in Thrombosis and Haemostasis, suggested that Boehringer Ingelheim's novel oral direct thrombin inhibitor dabigatran etexilate is cost-effective compared to current treatment options, particularly in real-world clinical practice.

25 Mar 2011

FDA approves Nordion's TheraSphere IDE for Phase III trial to treat HCC

Nordion Inc., a leading provider of products and services to the global health science market, today announced that it has received U.S. Food and Drug Administration approval to conduct a Phase III clinical trial for TheraSphere® under an Investigational Device Exemption.

23 Mar 2011

AHA to honor BIDMC investigator for groundbreaking Vascular Biology research

Alterations in blood vessel dilation lie at the heart of coronary artery health: When vessels dilate, blood and oxygen supplies successfully reach the heart. When vessels contract, blood and oxygen are diminished, leading to coronary artery disease.

23 Mar 2011

Dabigatran etexilate cost-effective compared to current care for stroke prevention in AF patients

A new health economic analysis, published today online in Thrombosis and Haemostasis, suggested that Boehringer Ingelheim's novel oral direct thrombin inhibitor, dabigatran etexilate, is cost-effective compared to current treatment options, particularly in "real-world" clinical practice.

23 Mar 2011

New scientific statement gives guidance to doctors for treatment of blood clots

Doctors are encouraged to consider therapies in addition to blood thinners to treat certain patients with potentially dangerous blood clots that form in the deep veins and travel to the lungs, according to a new scientific statement from the American Heart Association.

22 Mar 2011

Englewood Hospital and Medical Center earns HealthGrades Patient Safety Excellence Award

Englewood Hospital and Medical Center was identified as a recipient of the 2011 HealthGrades Patient Safety Excellence Award, indicating that its patient safety ratings are in the top 5% of U.S. hospitals.

18 Mar 2011

FibroGen, Astellas advance FG-4592 to phase 2b development for treatment of anemia in chronic kidney disease

FibroGen, Inc., today announced that FibroGen and partner Astellas Pharma Inc. advanced FG-4592 (Astellas designation ASP1517), an investigational anemia therapy, to phase 2b development for treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.

18 Mar 2011

Major breakthrough in thrombosis

Scientists from the University of Reading have announced a major breakthrough in understanding how to control blood clotting which could lead to the development of new treatments and save the lives of thousands of people each year.

17 Mar 2011

Argon acquires global rights to market, distribute Rex Medical's Option Retrievable Inferior Vena Cava Filter

Argon Medical Devices, Inc. announced today that it has entered into a definitive license agreement with Rex Medical, LP ("Rex Medical") for exclusive global rights to market and distribute the Option™ Retrievable Inferior Vena Cava Filter, an implantable device used in the prevention of Pulmonary Embolism (PE).

15 Mar 2011

BioInvent commences BI-204 phase II study in patients with acute coronary syndrome

BioInvent International AB announces today the dosing of the first patient in the phase II study of the Company's antibody, BI-204. The product candidate is being developed for secondary prevention of cardiovascular events in patients with acute coronary syndrome.

14 Mar 2011

Tamoxifen against breast cancer can save lives and reduce medical costs

Tamoxifen, taken by certain women as a preventive measure against breast cancer, saves lives and reduces medical costs. That is the conclusion of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

14 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Physical therapy within 24 hours of knee arthroplasty can improve recovery, cut hospital stays

Starting rehabilitation sooner following knee arthroplasty surgery could pay dividends - for both patients and hospitals. Commencing physical therapy within 24 hours of surgery can improve pain, range of joint motion and muscle strength as well as cut hospital stays, according to new research in the journal Clinical Rehabilitation, published by SAGE.

6 Mar 2011

Efficient medical treatments to be showcased at SIR's 36th Annual Scientific Meeting

The Society of Interventional Radiology will feature minimally invasive scientific advances and new discoveries in treating a host of diseases at its 36th Annual Scientific Meeting March 26–31 at McCormick Place (West) in Chicago, Ill. The theme of the meeting is "IR Rising: Leading Image-guided Medicine," chosen to reflect interventional radiology's continued revolutionizing of modern medicine.

5 Mar 2011

VDF urges Americans to learn about risks of DVT to help prevent death

Each year between 100,000-180,000 Americans die as the result of pulmonary embolism, a complication from blood clots in the lungs. The Vascular Disease Foundation urges Americans, especially women, to learn about the risks of venous blood clots to help prevent these deaths.

3 Mar 2011

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

Alexion Pharmaceuticals, Inc. joins the European Organization for Rare Diseases, the National Organization for Rare Disorders and families, governments, companies and medical communities around the world in observing the fourth annual Rare Disease Day today.

28 Feb 2011

Researchers to examine thrombolysis for treatment of DVT in leg

Blood clots in the leg occur commonly. In one-half of the cases, the blood clot will break loose and travel through the bloodstream to the lungs - which may be life-threatening.

28 Feb 2011

Thrombosis News and Research

Latest Thrombosis News and Research

Nordion presents TheraSphere Phase II trial results against liver metastases at SIR meeting

Drugs for prevention of breast cancer

Merck to return rights for betrixaban to Portola

Dabigatran etexilate is less costly, more effective for stroke treatment in patients with AF

FDA approves Nordion's TheraSphere IDE for Phase III trial to treat HCC

AHA to honor BIDMC investigator for groundbreaking Vascular Biology research

Dabigatran etexilate cost-effective compared to current care for stroke prevention in AF patients

New scientific statement gives guidance to doctors for treatment of blood clots

Englewood Hospital and Medical Center earns HealthGrades Patient Safety Excellence Award

FibroGen, Astellas advance FG-4592 to phase 2b development for treatment of anemia in chronic kidney disease

Major breakthrough in thrombosis

Argon acquires global rights to market, distribute Rex Medical's Option Retrievable Inferior Vena Cava Filter

BioInvent commences BI-204 phase II study in patients with acute coronary syndrome

Tamoxifen against breast cancer can save lives and reduce medical costs

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Physical therapy within 24 hours of knee arthroplasty can improve recovery, cut hospital stays

Efficient medical treatments to be showcased at SIR's 36th Annual Scientific Meeting

VDF urges Americans to learn about risks of DVT to help prevent death

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

Researchers to examine thrombolysis for treatment of DVT in leg

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Thrombosis News and Research

Latest Thrombosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in